FKPC-101 is under clinical development by CellVax Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FKPC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FK-PC101 is under development for the treatment of prostate cancer. The therapeutic candidate comprises irradiated autologous tumor cells which are administered through intradermal route.
CellVax Therapeutics overview
CellVax Therapeutics developing proprietary cell-based cancer immunotherapy candidate FK-PC101, for the treatment of prostate cancer patients.
For a complete picture of FKPC-101’s drug-specific PTSR and LoA scores, buy the report here.